You are using an outdated browser. Please upgrade your browser to improve your experience.

Tbio
ERVFRD-1
Syncytin-2

Protein Summary
Description
This endogenous retroviral envelope protein has retained its original fusogenic properties and participates in trophoblast fusion and the formation of a syncytium during placenta morphogenesis. The interaction with MFSD2A is apparently important for this process (PubMed:18988732). Endogenous envelope proteins may have kept, lost or modified their original function during evolution but this one can still make pseudotypes with MLV, HIV-1 or SIV-1 virions and confer infectivity. Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. The surface protein mediates receptor recognition, while the transmembrane protein anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (PubMed:14694139). Many different human endogenous retrovirus (HERV) families are expressed in normal placental tissue at hi ...more
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000472091
  • ENSP00000420174
  • ENSG00000244476
  • ENST00000542862
  • ENSP00000444461

Symbol
  • ERVFRDE1
  • envFRD
  • UNQ6191
  • ERVFRDE1
  • GLLL6191
  • HERV-FRD
  • HERV-W/FRD
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
microRNA
0.84
transcription factor
0.56
cellular component
0.51
chemical
0.44
virus perturbation
0.41


Protein Classes
No PANTHER Classes or DTO Classes found
IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 39.36   (req: < 5)
Gene RIFs: 20   (req: <= 3)
Antibodies: 124   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 39.36   (req: >= 5)
Gene RIFs: 20   (req: > 3)
Antibodies: 124   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 2
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0